| 1 |
34958553 | Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells. | 2022 Feb 2 |
1 |
| 2 |
35205643 | Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. | 2022 Feb 11 |
1 |
| 3 |
35359396 | Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer. | 2022 |
2 |
| 4 |
35557035 | Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). | 2022 May 3 |
1 |
| 5 |
33453391 | Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. | 2021 Apr |
1 |
| 6 |
33545804 | Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report. | 2021 Jan |
2 |
| 7 |
34301749 | Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. | 2021 Oct 15 |
2 |
| 8 |
34768353 | Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer. | 2021 Oct 21 |
1 |
| 9 |
34925959 | The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC). | 2021 |
1 |
| 10 |
31876893 | BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-Reply. | 2020 Mar 1 |
1 |
| 11 |
31876918 | BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab. | 2020 Mar 1 |
1 |
| 12 |
32173049 | Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. | 2020 May |
1 |
| 13 |
32371137 | 'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors. | 2020 Jul |
1 |
| 14 |
32717529 | The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction. | 2020 Oct 1 |
1 |
| 15 |
32963528 | BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. | 2020 |
1 |
| 16 |
30824427 | Niraparib Shrinks BRCA-Mutated Prostate Tumors. | 2019 Apr |
1 |
| 17 |
30948273 | Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. | 2019 May |
2 |
| 18 |
31191001 | Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. | 2019 |
1 |
| 19 |
31194225 | Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. | 2019 Aug 1 |
1 |
| 20 |
31466953 | Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. | 2019 Aug 28 |
1 |
| 21 |
31562799 | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. | 2019 Dec 19 |
1 |
| 22 |
32642648 | Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. | 2019 May-Dec |
3 |
| 23 |
33343988 | Rucaparib and Niraparib in Advanced Ovarian Cancer. | 2019 May-Jun |
2 |
| 24 |
29397193 | The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. | 2018 Apr |
2 |
| 25 |
29605737 | Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. | 2018 May |
1 |
| 26 |
29911447 | Niraparib for the treatment of ovarian cancer. | 2018 Aug |
1 |
| 27 |
30647846 | A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. | 2018 Dec 14 |
2 |
| 28 |
28631775 | [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.] | 2017 Jun |
1 |
| 29 |
29081841 | Niraparib in ovarian cancer: results to date and clinical potential. | 2017 Sep |
1 |
| 30 |
29138572 | Current status of poly(ADP-ribose) polymerase inhibitors and future directions. | 2017 |
1 |
| 31 |
29214031 | PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. | 2017 |
1 |
| 32 |
23810788 | The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. | 2013 Aug |
4 |
| 33 |
19873981 | Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. | 2009 Nov 26 |
2 |